Trial Profile
A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy (SWIPE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms SWIPE
- 22 Sep 2023 Last checked against European Clinical Trials Database record.
- 22 Sep 2023 Status changed from active, no longer recruiting to completed.
- 28 Jul 2023 Planned End Date changed from 31 Jul 2021 to 31 Dec 2023.